Associate Edward (Eddie) Block was quoted in a CNBC article, “Alarm in Texas as 23 towns hit by ‘coordinated’ ransomware attack,” about a coordinated series of ransomware attacks on 23 unidentified municipalities in the state.
Block, who previously served as the state’s chief information security officer, said he expects that officials are keeping the names of the affected municipalities a secret while they work to address the problem. “I would suspect that there are systems that are still being recovered,” he said. “[Going public] kind of paints a target on the back of those agencies” that other cybercriminals might seek to exploit.
Block, who previously served as the state’s chief information security officer, said he expects that officials are keeping the names of the affected municipalities a secret while they work to address the problem. “I would suspect that there are systems that are still being recovered,” he said. “[Going public] kind of paints a target on the back of those agencies” that other cybercriminals might seek to exploit.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”